The stock of Pelthos Therapeutics Inc (AMEX: PTHS) has increased by 60.33% when compared to last closing price of $16.18.Despite this, the company has seen a gain of 92.22% in its stock price over the last five trading days.
Is It Worth Investing in Pelthos Therapeutics Inc (AMEX: PTHS) Right Now?
The 36-month beta value for PTHS is at 3.69.
The average trading volume for PTHS on July 08, 2025 was 75.17K shares.
PTHS’s Market Performance
PTHS’s stock has seen a 92.22% increase for the week, with a 140.28% rise in the past month and a 84.87% gain in the past quarter. The volatility ratio for the week is 65.28%, and the volatility levels for the past 30 days are at 25.34% for Pelthos Therapeutics Inc The simple moving average for the past 20 days is 92.99% for PTHS’s stock, with a 121.11% simple moving average for the past 200 days.
PTHS Trading at 117.28% from the 50-Day Moving Average
After a stumble in the market that brought PTHS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.71% of loss for the given period.
Volatility was left at 25.34%, however, over the last 30 days, the volatility rate increased by 65.28%, as shares surge +141.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +89.42% upper at present.
During the last 5 trading sessions, PTHS rose by +92.22%, which changed the moving average for the period of 200-days by +205.29% in comparison to the 20-day moving average, which settled at $13.45. In addition, Pelthos Therapeutics Inc saw 104.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTHS starting from Malamut Richard, who purchase 10,400 shares at the price of $0.94 back on Sep 12 ’24. After this action, Malamut Richard now owns 91,565 shares of Pelthos Therapeutics Inc, valued at $9,825 using the latest closing price.
Francis Knuettel II, the CEO, Pres., CFO, Treas & Secty of Pelthos Therapeutics Inc, purchase 3,500 shares at $0.97 during a trade that took place back on Sep 13 ’24, which means that Francis Knuettel II is holding 547,710 shares at $3,395 based on the most recent closing price.
Stock Fundamentals for PTHS
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.39.
Conclusion
In conclusion, Pelthos Therapeutics Inc (PTHS) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
